Herbert Smith Freehills advised SF Holding on the deal, while Clifford Chance advised the underwriters. S.F. Holding Co., Ltd. completed its global offering and listing on...
S.F. Holding’s $750 Million IPO On HKSE
TS Lines’ IPO on Hong Kong Stock Exchange
Herbert Smith Freehills advised joint sponsors on T.S. Lines’ Hong Kong IPO. T.S. Lines Limited (02510.HK) completed its listing on the Main Board of the Hong...
China Huaneng Group’s $500m Issuance in 5.30% Perpetual Bonds
Herbert Smith Freehills advised China Huaneng Group on US$500 million perpetual bond offering. China Huaneng Group Co., Ltd successfully issued US$500 million in 5.30% subordinated guaranteed...
Cutia Therapeutics’ IPO on Hong Kong Market
Herbert Smith Freehills has advised the sole sponsor and the overall coordinators on the listing. Cutia Therapeutics, a company with operations in Beijing, Hong Kong, Shanghai,...
MedSci Healthcare Holdings Limited’s Mainboard Listing on the Hong Kong Stock Exchange
Herbert Smith Freehills has advised China International Capital Corporation Hong Kong Securities Limited, and Macquarie Capital Limited. MedSci Healthcare operates one of the largest online professional...
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.’s Listing on the Main Board of the Hong Kong Stock Exchange
Herbert Smith Freehills has advised China International Capital Corporation as the sole sponsor on the listing of LEPU ScienTech Medical Technology while Wilson Sonsini Goodrich &...
Jenscare Scientific’s Hong Kong IPO
O’Melveny represented Jenscare Scientific Co., Ltd on the deal. Herbert Smith Freehills advised China International Capital Corporation and Citigroup. Jenscare Scientific Co., Ltd. (9877.HK) announced its...
Onewo’s US$738 Million Hong Kong IPO
Paul Hastings and JunHe advised Onewo Inc. on the deal. Herbert Smith Freehills advised CITIC Securities, Citigroup and Goldman Sachs as joint sponsors. Onewo Inc. announced its approximately...
Biocytogen Pharmaceuticals’ Listing on the Main Board of the Hong Kong Stock Exchange
Herbert Smith Freehills has advised Goldman Sachs and China International Capital Corporation as joint sponsors and underwriters. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announced the company’s official listing...
Rainmed Medical’s HK$146 Million IPO and Listing on the Hong Kong Stock Exchange
O’Melveny and Grandall represented Rainmed Medical Limited (2297.HK) on the deal. Herbert Smith Freehills has advised Huatai Financial Holdings. Rainmed Medical Limited (2297.HK) announced its US$19...
Yunkang Group Limited’s $140 Million Hong Kong Listing
Kirkland & Ellis and Zhong Lun advised Yunkang Group Limited on the deal. Herbert Smith Freehills advised CMB International Capital Limited and SPDB International Capital Limited....
Lepu Biopharma’s US$116.1 Million Hong Kong IPO and Listing
Clifford Chance has advised Lepu Biopharma Co., Ltd. on the deal. Herbert Smith Freehills has advised CICC and Morgan Stanley. The Joint Sponsors are CICC and...